Mode
Text Size
Log in / Sign up

AI-derived echocardiographic measurements predict outcomes in transthyretin cardiomyopathy patientsAI Echo Scan Predicts Heart Failure Risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that AI-derived echocardiographic measurements are independent prognostic predictors in ATTR-CM patients.

This retrospective study analyzed data from 347 patients enrolled in two ATTR-CM registries. The primary exposure involved AI-derived echocardiographic measurements, specifically left ventricular global longitudinal strain (LV-GLS) and right ventricular fractional area change (RV FAC), alongside an AI Echo staging system. These were compared against human measurements and biomarker-based NAC staging adjusted for age. The median follow-up duration was 2.4 years, with the primary outcome defined as all-cause death or heart failure hospitalization.

Results indicated that AI-derived LV-GLS was an independent outcome predictor, with a hazard ratio of 1.13 (95% CI 1.03-1.25, p=0.011) per unit increase. Conversely, RV FAC showed a decreased hazard, with a hazard ratio of 0.96 (95% CI 0.93-0.99, p=0.014). Regarding the Echo staging system, intermediate risk was associated with a 3-fold increased hazard (95% CI 1.70-5.91), while high risk demonstrated a 6-fold increased hazard (95% CI 3.22-10.30) compared to low risk. The incremental prognostic value was significant, with the chi-square statistic increasing from 53 to 80 (p<0.001). Predictive performance at one year was comparable between AI and human measurements, with no significant difference observed (all p>0.05).

No safety data, adverse events, or discontinuations were reported in this study. Key limitations include the retrospective design, which precludes causal inference, and the fact that the prognostic value of these metrics prior to this study was unknown. The findings support the integration of these AI tools into clinical risk stratification for transthyretin cardiomyopathy, though the association between measurements and outcomes remains observational.

The Quiet Heart Problem

Imagine your heart is a tireless pump that works every second of your life. For many people, it works perfectly until one day it struggles. This is the reality for those with transthyretin cardiomyopathy, or ATTR-CM.

This condition is a slow-growing disease where proteins build up in the heart muscle. It is often called "silent" because patients might feel fine for years before symptoms appear. By the time chest pain or shortness of breath starts, the damage is already done.

Doctors currently use standard heart scans called echocardiograms to check these patients. These scans look at the heart's structure and how well it pumps blood. However, looking at a scan is hard work for a doctor. It takes time and focus to measure every part of the heart correctly.

What We Used to Know

For a long time, doctors relied on blood tests and basic scan measurements to guess how sick a patient was. They used a system called NAC staging. This system looks at blood markers to group patients into risk levels.

But here is the twist. Blood tests alone do not tell the whole story. Two patients with the same blood test results could have very different heart health. One might be stable, while the other is on the verge of a crisis. Doctors needed a better way to see inside the heart muscle itself.

The New Twist

This study changes the game by using artificial intelligence to read those scans. Instead of a doctor measuring every line on a screen, a smart computer does it instantly. It looks for tiny changes in how the heart muscle stretches and squeezes.

Think of the heart muscle like a rubber band. When it is healthy, it stretches and snaps back perfectly. In ATTR-CM, the protein buildup makes the rubber band stiff. The AI measures exactly how much it stretches. It finds problems that the human eye might miss.

How the Computer Sees It

The AI acts like a super-focused magnifying glass. It measures two specific things: how the left side of the heart stretches and how the right side squeezes.

The study used a simple two-step check. If both measurements look normal, the patient is in a low-risk group. If one looks off, they are in an intermediate group. If both are abnormal, they are in a high-risk group.

This is like checking a car's engine. You don't just listen to the noise; you check the oil pressure and temperature. The AI checks the "pressure" of the heart muscle to see if it is struggling.

The Study in Brief

Researchers looked at records from 347 patients who had this heart condition. Most were men, and the average age was 78 years old. They used the AI software to read the heart scans from the start of their treatment.

The team followed these patients for about two and a half years. They tracked who needed hospital care for heart failure or who passed away. They compared the AI results with the old blood test methods to see which was better.

The findings were clear and important. The AI measurements predicted who would get sick much better than blood tests alone. Patients in the high-risk group based on the scan were six times more likely to have bad outcomes than those in the low-risk group.

That is a huge difference. It means doctors can spot trouble early. They can step in with new medicines before the heart fails completely. The AI found warning signs that the old system missed.

But There Is a Catch

This doesn't mean this treatment is available yet. The study was done on past records, not on patients getting care today. It shows the technology works, but hospitals need to buy the software and train their staff.

What Experts Say

The researchers noted that the computer did just as well as a human doctor. In fact, the computer was faster and very consistent. Human doctors sometimes get tired or miss small details. The AI does not get tired. It looks at every pixel of the scan with perfect focus.

This fits into the bigger picture of using smart tools to help doctors. It does not replace the doctor; it gives them a powerful second opinion. It helps ensure every patient gets the right level of care based on their actual heart health.

If you or a loved one has ATTR-CM, this is good news for the future. It means risk assessment will become much more accurate. You might get caught earlier in the disease process.

Talk to your doctor about your heart health. Ask if your hospital uses advanced imaging. Remember, early detection is the key to managing this condition. Do not wait for symptoms to appear.

Limitations to Remember

This study looked at data from two specific registries. It did not include every type of patient in the world. Also, the AI tool used is not approved for general use yet. It is still in the testing phase.

Next, researchers will test this AI tool in real-time hospital settings. They want to see if it works when doctors are busy and tired. If it proves safe and effective, it could become a standard part of heart care.

Getting approval takes time. Regulators need to be sure the tool is safe for everyone. But the path is clear. Smart tools are coming to help protect your heart.

Study Details

Sample sizen = 347
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Transthyretin cardiomyopathy (ATTR-CM) is a progressive, potentially fatal disease requiring accurate risk stratification. Echocardiography is the first-line imaging modality, with AI-based tools increasingly applied for automated analysis, yet their prognostic value remains unknown. Objectives: To examine the prognostic value of AI-derived echocardiographic measurements and their incremental value beyond biomarker staging in ATTR-CM. Methods: This retrospective study included patients from two ATTR-CM registries. Baseline echocardiograms were analyzed using the fully automated AI-based software Us2.ai. Prognostic performance was assessed by Kaplan-Meier analysis, Cox regression, and ROC curves. A two-parameter echocardiographic staging system combining left ventricular (LV) global longitudinal strain (GLS) and right ventricular (RV) fractional area change (FAC) stratified patients into low (both normal), intermediate (one abnormal), and high risk (both abnormal). Results: Among 347 patients (91% male, median age 78 years), 141 experienced all-cause death or heart failure hospitalization over a median follow-up of 2.4 years. In multivariable analysis, AI-derived LV-GLS (HR 1.13 [1.03-1.25], p=0.011) and RV FAC (HR 0.96 [0.93-0.99], p=0.014) were independent outcome predictors. Echo staging stratified risk into groups with 3-fold (95% CI 1.70-5.91) and 6-fold (95% CI 3.22-10.30) increased hazard compared to low risk (p<0.001), with incremental prognostic value beyond National Amyloidosis Centre (NAC) staging and age (chi-square from 53 to 80; p<0.001). AI and human measurements showed comparable 1-year predictive performance (all p>0.05). Conclusion: AI-derived echocardiographic measurements demonstrate independent and incremental prognostic value beyond biomarker-based NAC staging in ATTR-CM, comparable to human measurements, supporting their integration into clinical risk stratification.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.